ALERT: This system is being upgraded on Tuesday December 12. It will not be available
for use for several hours that day while the upgrade is in progress. Deposits to DukeSpace
will be disabled on Monday December 11, so no new items are to be added to the repository
while the upgrade is in progress. Everything should be back to normal by the end of
day, December 12.
Development and Characterization of a Luciferase Labeled, Syngeneic Murine Model of Ovarian Cancer.
Abstract
Despite advances in surgery and targeted therapies, the prognosis for women with high-grade
serous ovarian cancer remains poor. Moreover, unlike other cancers, immunotherapy
has minimally impacted outcomes in patients with ovarian cancer. Progress in this
regard has been hindered by the lack of relevant syngeneic ovarian cancer models to
study tumor immunity and evaluate immunotherapies. To address this problem, we developed
a luciferase labeled murine model of high-grade serous ovarian cancer, STOSE.M1 luc.
We defined its growth characteristics, immune cell repertoire, and response to anti
PD-L1 immunotherapy. As with human ovarian cancer, we demonstrated that this model
is poorly sensitive to immune checkpoint modulators. By developing the STOSE.M1 luc
model, it will be possible to probe the mechanisms underlying resistance to immunotherapies
and evaluate new therapeutic approaches to treat ovarian cancer.
Type
Journal articleSubject
STOSEhigh-grade serous
immune profiling
immunotherapy
intraperitoneal
murine
ovarian cancer
ovarian intrabursal
syngeneic
Permalink
https://hdl.handle.net/10161/25943Published Version (Please cite this version)
10.3390/cancers14174219Publication Info
(2022). Development and Characterization of a Luciferase Labeled, Syngeneic Murine Model of
Ovarian Cancer. Cancers, 14(17). pp. 4219. 10.3390/cancers14174219. Retrieved from https://hdl.handle.net/10161/25943.This is constructed from limited available data and may be imprecise. To cite this
article, please review & use the official citation provided by the journal.
Collections
More Info
Show full item recordScholars@Duke
Ching-yi Chang
Associate Research Professor of Pharmacology and Cancer Biology
The main focus of my research has been to define the roles of nuclear hormone receptors
(NHRs) in the pathogenesis of disease, with a focus on hormone-related cancers.
During earlier stages of my research career, definition of the structural and molecular
determinants of NHR receptor biology and pharmacology was the main focus. Information
obtained from these studies was used to guide the development of receptor modulators
for therapeutic interventions and to gain insights
Donald Patrick McDonnell
Glaxo-Wellcome Distinguished Professor of Molecular Cancer Biology, in the School
of Medicine
Lab WebsiteThe research in our group is focused on the development and application
of mechanism based approaches to identify novel therapeutics for use in the treatment
and prevention of hormonally responsive cancers. Specifically we are interested in
the pharmaceutical exploitation of the estrogen and androgen receptors as therapeutic
targets in breast and prostate cancers and in defining how these receptors influence
the pathoge
Pamela Nicole Peters
Clinical Associate in the Department of Obstetrics and Gynecology
Rebecca A Previs
Adjunct Assistant Professor in the Department of Obstetrics and Gynecology
Suzanne E Wardell
Assistant Research Professor of Pharmacology & Cancer Biology
Throughout my career in science, my work has focused in aspects of steroid hormone
(progesterone, estrogen, or androgen) receptor activity in breast and prostate cancers.
These interests include not only mechanistic studies of receptor activity in treatment
naive tumors, but also the role of these receptors in the evolution of resistance
to current therapies.Despite the development of improved therapies, breast cancer
remains a leading cause of mortality in women. While a majority of
Alphabetical list of authors with Scholars@Duke profiles.
Articles written by Duke faculty are made available through the campus open access policy. For more information see: Duke Open Access Policy
Rights for Collection: Scholarly Articles
Works are deposited here by their authors, and represent their research and opinions, not that of Duke University. Some materials and descriptions may include offensive content. More info